Our results, for the first time, reveal that CXCR6 expression in CD8+MAIT cells may be associated with the sensitivity of patients with NSCLC to immunotherapy and shed light on new predictive biomarkers for anti-PD-1/PD-L1 therapy. This evidence concerns the gene CXCR6 and non-small cell lung carcinoma.